Cargando…

Remaining challenges in HCV elimination

Detalles Bibliográficos
Autores principales:	Capraru, Camelia, Feld, Jordan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Materias:	Hepatology Snapshot
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880835/ https://www.ncbi.nlm.nih.gov/pubmed/33589319 http://dx.doi.org/10.1016/j.jhep.2020.11.051

Ejemplares similares

Personalized medicine in nonalcoholic fatty liver disease
por: Pirola, Carlos J., et al.
Publicado: (2022)

History and future of hepatitis B virus control in South Korea
por: Kim, Do Young
Publicado: (2021)

Hepatocellular carcinoma statistics in South Korea
por: Chon, Young Eun, et al.
Publicado: (2021)

Diagnostic and therapeutic algorithm for pulmonary arterial hypertension
por: Desai, Ankit A., et al.
Publicado: (2011)

Drugs currently used for treatment of PAH
por: Desai, Ankit, et al.
Publicado: (2011)

Survival in pulmonary arterial hypertension: A brief review of registry data
por: Pauwaa, Sunil, et al.
Publicado: (2011)

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man
por: Cimaglia, Paolo, et al.
Publicado: (2022)

Current status and outcome of liver transplantation in South Korea
por: Choi, Ho Joong
Publicado: (2022)

Acute on chronic liver failure in cirrhosis
por: Tonon, Marta, et al.
Publicado: (2022)

Microbiome and metabolomics in alcoholic liver disease
por: Ganesan, Raja, et al.
Publicado: (2022)

Systemic therapy in advanced hepatocellular carcinoma
por: Ahn, Joseph C., et al.
Publicado: (2023)

The role of the hepatic autonomic nervous system
por: Luo, Qiankun, et al.
Publicado: (2023)

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Epidemiology and updated management for autoimmune liver disease
por: Heo, Nae-Yun, et al.
Publicado: (2023)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Mapping Chronic Disease Risk Factors With ArcGIS Online in Support of COVID-19 Response in Florida
por: DuClos, Chris, et al.
Publicado: (2021)

SnapShot: COVID-19
por: Oberfeld, Blake, et al.
Publicado: (2020)

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C
por: Isfordink, Cas J, et al.
Publicado: (2020)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
por: Ahlén, G, et al.
Publicado: (2009)

Signaling at the endosome: cryo‐EM structure of a GPCR–G protein–beta‐arrestin megacomplex
por: Nguyen, Anthony H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_abmu56agd88inc7pv3b26qd0h1